
via Pixabay
Researchers say how quickly a person’s pupil dilates while taking cognitive tests
Alzheimer’s disease (AD) begins to alter and damage the brain years — even decades — before symptoms appear, making early identification of AD risk paramount to slowing its progression.
In a new study published online in the September 9, 2019 issue of the Neurobiology of Aging, scientists at University of California San Diego School of Medicine say that, with further developments, measuring how quickly a person’s pupil dilates while they are taking cognitive tests may be a low-cost, low-invasive method to aid in screening individuals at increased genetic risk for AD before cognitive decline begins.
In recent years, researchers investigating the pathology of AD have primarily directed their attention at two causative or contributory factors: the accumulation of protein plaques in the brain called amyloid-beta and tangles of a protein called tau. Both have been linked to damaging and killing neurons, resulting in progressive cognitive dysfunction.
The new study focuses on pupillary responses which are driven by the locus coeruleus (LC), a cluster of neurons in the brainstem involved in regulating arousal and also modulating cognitive function. Tau is the earliest occurring known biomarker for AD; it first appears in the LC; and it is more strongly associated with cognition than amyloid-beta. The study was led by first author William S. Kremen, PhD, and senior author Carol E. Franz, PhD, both professors of psychiatry and co-directors of the Center for Behavior Genetics of Aging at UC San Diego School of Medicine.
The LC drives pupillary response — the changing diameter of the eyes’ pupils — during cognitive tasks. (Pupils get bigger the more difficult the brain task.) In previously published work, the researchers had reported that adults with mild cognitive impairment, often a precursor to AD, displayed greater pupil dilation and cognitive effort than cognitively normal individuals, even if both groups produced equivalent results. Critically, in the latest paper, the scientists link pupillary dilation responses with identified AD risk genes.
“Given the evidence linking pupillary responses, LC and tau and the association between pupillary response and AD polygenic risk scores (an aggregate accounting of factors to determine an individual’s inherited AD risk), these results are proof-of-concept that measuring pupillary response during cognitive tasks could be another screening tool to detect Alzheimer’s before symptom appear,” said Kremen.
Learn more: How the Eyes Might Be Windows to the Risk of Alzheimer’s Disease
The Latest on: Diagnosing Alzheimer’s
[google_news title=”” keyword=”diagnosing Alzheimers” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Diagnosing Alzheimer’s
- Roche, Lilly To Develop Elecsys Amyloid Plasma Panel To Boost Early Diagnosis Of Alzheimer's Diseaseon March 22, 2023 at 12:26 am
Swiss drug major Roche Holding AG (RHHBY) announced Wednesday that it has entered into a collaboration to support the development of ...
- F. Hoffmann-La Roche Ltd: Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's diseaseon March 21, 2023 at 11:10 pm
The EAPP is an innovative blood test that aims to facilitate the earlier diagnosis of Alzheimer's disease. Today, barriers to early and accurate diagnosis of Alzheimer's exist across the globe with up ...
- Roche teams up with Lilly to validate Alzheimer's blood teston March 21, 2023 at 11:10 pm
Roche and Eli Lilly and Co are joining forces to develop a blood test for Alzheimer's disease, and plan to kick off a two-year clinical trial involving hundreds of volunteers with the aim of winning U ...
- Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's diseaseon March 21, 2023 at 10:59 pm
Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma PanelThe Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing ...
- Girardi prosecutors question Alzheimer's diagnosis as defense asks to limit evaluationon March 21, 2023 at 2:17 pm
Federal prosecutors in Los Angeles are casting doubt on disbarred California lawyer Tom Girardi's Alzheimer's diagnosis as they wrangle over how to test his competency to stand trial for allegedly ...
- Memory Café provides support for early stage dementia and Alzheimer’s patientson March 21, 2023 at 11:59 am
The Alzheimer’s Association hosted its monthly Memory Café. The café accompanied by a support group is an initiative aimed at providing support for individuals with Dementia.
- Alzheimer’s report hints at a future health crisis bigger than COVID-19on March 21, 2023 at 6:04 am
Census projections for America’s rapidly aging population suggest the scope of the disease soon might rival what America saw during the height of the COVID-19 pandemic.
- RI Hospital seeking participants for new Alzheimer’s studyon March 20, 2023 at 1:16 pm
A study out of Rhode Island Hospital aims to use saliva as a way to help researchers identify early brain changes indicative of Alzheimer’s disease.
- Alzheimer’s caregiver: ‘You can’t prepare yourself for when the person you love forgets who you are’on March 20, 2023 at 6:28 am
The Alzheimer’s Association released its annual report on Wednesday, March 15. According to the report, over 11 million Americans provided unpaid care for people with Alzheimer’s and dementia in 2022.
- Researchers working toward live CTE diagnosis: Alzheimer's Q&Aon March 20, 2023 at 3:30 am
CTE has been in the forefront lately with widespread media attention as many well-known football players are coming forward in declaration of their personal journey with the condition, and it was ...
via Bing News